| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Acadia Pharmaceuticals Inc. (ACAD) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. ACAD is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 66.1K | $1.88M | - | |
| 10% | 32.0K | $910.6K | - | |
| VP | 19.0K | $540.4K | -16,558 | |
| CEO | 14.8K | $421.1K | - | |
| Other | 13.1K | $372.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2018 | Baity Glenn | EVP And GC | Sale+OE | 74,321 | $30.14 | $2,240,138.99 | -51.5% | |
| Jan 2, 2018 | Brege Laura62 | Director | Sale+OE | 25,000 | $30.06 | $751,542.50 | -100% | |
| Oct 5, 2017 | Baity Glenn | EVP And GC | Sale+OE | 37,500 | $40.91 | $1,534,042.50 | -35.0% | |
| Aug 30, 2017 | Baity Glenn | EVP And GC | Sale+OE | 26,507 | $34.87 | $924,314.99 | -28.2% | |
| Aug 9, 2017 | Baity Glenn | EVP And GC | Sale+OE | 14,322 | $34.88 | $499,534.17 | -15.6% | |
| Jul 20, 2017 | Baity Glenn | EVP And GC | Sale+OE | 38,097 | $30.00 | $1,142,910.00 | -34.9% | |
| Jun 22, 2017 | Baity Glenn | EVP And GC | Sale+OE | 1,903 | $30.00 | $57,090.76 | -2.3% | |
| Feb 21, 2017 | Moore Terrence O | EVP, Chief Commercial Officer | Sale+OE | 7,856 | $39.65 | $311,490.40 | -82.5% | |
| Feb 16, 2017 | Moore Terrence O | EVP, Chief Commercial Officer | Sale+OE | 157,540 | $39.77 | $6,265,094.58 | -96.9% | |
| Feb 14, 2017 | Baity Glenn | EVP And GC | Sale+OE | 26,365 | $39.66 | $1,045,517.26 | -28.2% |